See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Tariffs
Nintendo
Donald Trump
Natural Disasters
Republican Party
Social Media
Baseball
Democratic Party
US Politics
Artificial Intelligence
European Union
Senate
Published • loading... • Updated

Nicox announces last patient completed final visit in Whistler Phase 3b clinical trial

Summary by ophthalmologytimes.com
The novel nitric oxide-donating bimatoprost eye drop is being clinically developed for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
ophthalmologytimes.comophthalmologytimes.com

Nicox announces last patient completed final visit in Whistler Phase 3b clinical trial

The novel nitric oxide-donating bimatoprost eye drop is being clinically developed for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

ophthalmologytimes.com broke the news in on Monday, March 24, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Whistler

Whistler

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal